Sanofi SA's Fiscal Year is From January To December - All Figures are in EUR, Billions.
The item "Interest-Expense" stands at 0.945 Billion Euros for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 12/31/2023.
Sanofi SA's third quarter result of 0.227 Billion EUR for the item "Interest Expense" represents an increase of 5.09 percent compared to it's second quarter result.
Also, Sanofi SA's third quarter result of 0.227 Billion EUR for the item "Interest Expense" represents a decrease of -14.34 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Sanofi SA's third quarter result of 0.945 Billion EUR for the item "Interest Expense" represents a decrease of -3.87 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -15.55 percent compared to the value the year prior.
The 1 year change in percent is -15.55.
The 3 year change in percent is 74.68.
The 10 year change in percent is 72.45.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Interest Expense | 905,699,262,464.00 |
![]() | Johnson & Johnson - Interest Expense | 486,508,953,600.00 |
![]() | AbbVie Inc - Interest Expense | 399,570,305,024.00 |
![]() | Roche Holding AG - Interest Expense | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Interest Expense | 280,205,508,085.11 |